Prospects for drug treatment of AIDS

Saudi Pharmaceutical Journal

Volumn 7, Issue 3, 1999, Pages 77-102

  Badary, Osama Ahmed ^a  

^a Al Azhar University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CHEMOPROPHYLAXIS; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; PNEUMOCYSTIS PNEUMONIA; REGULATOR GENE; REVIEW; SEROCONVERSION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

EID: 0032743120     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (200)

1. Barre-Sinouss F, Chermann JC, Rey F, Nugeyre MT, Vezinet-Brun F, Rouzioux C, Rozenbaum W and Montangier L Isolation of a T-lymphocyte retrovirus from a patient at a risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-871.
2. Gelderblom HR Assembly and morphology of HIV: potential effect of structure on viral function. AIDS 1991; 5:617-638.
3. Takasaki T, Kurane I, Aihara H, Ohkaw N and Yamaguchi J. Electron microscopic study of human immunodeficiency virus type-1 (HIV-1) core structure: two RNA strands in the core of mature and budding particles. Arch Virol 1997; 142:375-382.
4. Henderson LE, Bower MA, Sowder RC, Serabin SA, Johnson DG, Bess JW, Arthur LO, Bryant DK and Fenselau C. Gag proteins of the highly replicative MN strains of human immunodeficiency virus type 1: posttranscriptional modifications, proteorytic processing and complete amino acid sequences. J Virol 1992; 66:1826-1865.
5. Gurtler L. Recent aspects of HIV and HIV-related diseases. Infection 1997; 25:71-73.
6. Poulsen AG, Aaby P, Larsen O, Jensen H, Naucler A, Lisse IM, Christiansen CB, Dias F and Melbye M. 9-year HIV-2-associated mortality in an urban community in Bissau. West Africa. Lancet 1997; 349:911-914.
7. Zenkeng L, Gurthler L, Afan Ze E, Sam-Abbenyi A, Mbouni-Essomba G, Mpoundi-Ngolle E, Monny-Lobe M, Tapko JB and Kaptue L. Prevalence of HIV-1 subtype O infection in Cameroon: Preliminary results. AIDS 1994; 8:1626-1628.
8. Takamatsu J. HIV infection and acquired immunodeficiency syndrome. Rinsho Byori 1997; 45:409-414.
9. Quinn TC. Global burden of the HIV pandemic. Lancet 1996; 348:99-106.
10. Lindsay MK and Nesheim SR. Human immunodeficiency virus infection in pregnant women and their newborns. Clin Perinatol 1997; 24:161-180.
11. Aquaro S, Perno C, Balestra E, Balzarini J, Canci A, Francesconi M, Panti S, Sera F, Villani N and Calio R. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 1997; 62:138-143.
12. Bowers K, Pitcher C and Marsh M. CD4: A co-receptor in the immune response and HIV infection. Int J Biochem Cell Biol 1997; 29:871-875.
13. 13.Moore JP, Trkola A and Dragic T. Co-receptors for HIV entry. Curr Opin Immunol 1997; 9:551-562.
14. Zhang L, Carruthers CD, He T, Haung Y, Cao Y, Wong G, Hahn B and Ho DD. HIV type-1 subtypes, coreceptor usage and CCR% polymorphism. AIDS Res Hum Retroviruses 1997; 13:1357-1360.
15. Arnold E, Das K, Ding J, Yudav P, Hsiou Y, Boyer P and Hughes S. Targeting HIV reverse transcriptase for anti-AIDS drug design: structural and biological considerations for chemotherapeutic strategies. Drug Des 1996; Discv 13:29-47.
16. Dyda F, Hickman AB and Jenkins TM. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266:1981-1986.
17. Katz RA and Skalka AM. The retroviral enzymes. Ann Rev Biochem 1994; 63:133-173.
18. Mazumder A, Neamati N, Sommadassi J, Gasselin G, Schinazi R, Imbach J and Pommier Y. Effects of nucleotide analogues on human immunodeficiency virus type 1 integrase. Mol Pharmacol 1996; 49:621-628.
19. Cavallaro U, Mariotti M, Wu Z, Soria M and Maier J. Fibronectin modulates endothelial response to HIV type Tat AIDS Res Hum Retroviruses 1997; 13:1341-1348.
20. Kashanachi F, Sadaie MR and Brady JM. Inhibition of HIV transcription and virus replication using soluble Tat peptide analogues. Virology 1997; 227:431-438.
21. Moyle G and Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51:701-712.
22. McDonald CK and Kuritzkes DR Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997; 157:951-959.
23. Conn JA. Recent advances HIV infection-I BMJ 1997; 314:487-491.
24. Paul ME. Perspective: Research highlights at Baylor center for AIDS research. The immune system in vertical HIV infection: the immune response and disease progression. AIDS Res Hum Retroviruses 1997; 13:1-4.
25. Veugelers PJ and Schechter MT. The incubation period of HIV infection. Curr Opin Infect Dis 1997; 10:7-11.
26. Perelson AS, Neumann AU, Markowitz M, Leonard JM and Ho DD. HIV dynamics in vivo:virion clearance rate, infected cell life-span and viral generation time. Science 1996; 271:1582-1586.
27. Pontesilli O, Klein MR, Kerkhof-Grade SR, Pakker NG, de Wolf F, Schuitemaker H and Midema F. Kinetics of immune functions and virus replication during HIV-1 infection. Immunol Lett 1997; 57:125-130.
28. Ameisen JC, Estaquier J, Idziorek T and De Bels F. The relevance of apoptosis to AIDS pathogenesis. Trends Cell Biol 1995; 5:27-32.
29. Oyaizu JC and Pahwa S. Role of apoptosis in HIV disease pathogenesis. J Clin Immunol 1995; 15:217-231.
30. Busch MP and Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102:117-124.
31. Levy JA. Plasma viral load, CD4 cell counts, and HIV-1 production by cells. Science 1996; 271:670-671.
32. Famularo G, De Simone C and Marcellini S. Apoptosis: mechanisms and relation to AIDS. Med Hypotheses 1997; 48:423-429.
33. Thatte U and Dahanukar S. Apoptosis: clinical relevance and pharmacological manipulation. Drugs 1997; 54:511-532.
34. Baumler CB, Herr I, Bohler T, Krammer PH and Debatin KM. Increased CD95 (APO-1/Fas) ligand expression in T cells of HTV-1 infected children. Blood 1996; 88:1741-1748.
35. Peter ME, Ehret A, Berndt C and Krammer PH. AIDS and thew death receptors. Br Med Bul 1997; 52:604-616.
36. Degols G, Leonetti JP, Milhaud P, Mechti N and Lebleux B. Antisense inhbition of HIV: problems and perspectives. Antiviral Res 1992; 17:279-287.
37. Pallares-Trujillio J, Lopez-Soriano FJ and Argiles JM. TNF and AIDS: Two sides of the same coin? Med Res Rev 1995; 15:533-546.
38. Ekert PG and Voux DL. Apoptosis and the immune system. Br Med Bul 1997; 53:591-603.
39. Young LS, Dawson CW and Eliopoulos AG. Viruses and apoptosis. Br Med Bul 1997; 53:509-521.
40. Li CJ, Friedman DJ, Wang C, Metelev V and Pardee AB. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science 1995; 268:429-431.
41. Ensoli B, Buonaguro L and Barillar G. Release, uptake and effects of extracellular HIV-1 Tar protein on cell growth and viral transactivation. J Virol 1993; 67:277-287.
42. Abou-Shaaban RA. Oxidative stress, HIV and AIDS: The basis for antioxidant-oriented antiretroviral nucleoside analogues. SPJ 1995; 3:1-22.
43. Westendrop MO, Shatrov VA and Schulze-Osthoff K. HIV-1 Tat potentiates TNF-induced NF-κ activation and cytotoxicity by altering cellular redox state. EMBO J 1995; 14:546-554.
44. Ehret A, Westendrop MO and Herr I. Resistance of chimpanzee T cell to human immunodeficiency virus type-1 tat-enhanced oxidative stress and apoptosis. J Virol 1996; 70:6502-6507.
45. McDonnel NB, De Guzman RN, Rice WG, Turpin JA and Summers MF. Zinc ejection as a new rationale for the use of cystamine and related disulfide-containing antiviral agents in the treatment of AIDS. J Med Chem 1997; 40:1969-1976.
46. Hori K, Hatfield D. Maldarelli F, Lee BJ and Clouse KA. Selenium supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses 1997; 13:1325-1332.
47. Barnes PJ. Nuclear factor-κB. Int J Biochem Cell Biol 1997; 29:867-870.
48. Grimm S, Bauer MKA, Baeuerle PA and Schulze-Odthoff K. Bcl-2 down-regulates the activity of transcription factor NF-κB induced upon apoptosis. J Cell Biol 1996; 134:13-23.
49. Limbourg FP, Stadtler G, Chinnadurai G, Baeuerle PA and Schmitz ML. A hydrophobic region of the adenovirus E1B 19 kDa protein is necessary for the transient inhibition of NF-κB activated by different stimuli. J Biol Chem 1996; 271:20392-20398.
50. Peterhans E. Reactive oxygen species and nitric oxide in viral diseases. Biol Trace Elem Res 1997; 56:107-116.
51. Orlikowsky T, Wang Z, Dudhane A, Horowitz H, Riethmuller G and Hoffmann MK. Cytotoxic monocytes in the blood of HIV type 1-infected subjects destroy targeted T cells in a CD95-dependent fashion. AIDS Res Hum Retroviruses 1997; 13:953-958.
52. Alnemri ES, Livingstone DJ and Nicholson DW. Human ICE/CED-3 protease nomenclature. Cell 1996; 87:171.
53. Cahill MA, Peter ME and Kischkel FC. CD95 (APO-1/Fas) induces activation of SAP kinases downstream ICE-like proteases. oncogene 1996; 13:2087-2096.
54. Chinnalyan AM, Woffendin C, Dixit VM and Nabel GJ. The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med 1997; 3:333-337.
55. Mildvan D. Landay A, De Gruttola V, Machado SG and Kagass J. An approach to the validation of markets for use in AIDS clinical trials. Clin Infect Dis 1997; 24:764-774.
56. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997; 126:939-945.
57. Saag MS. Use of HIV viral load in clinical practice: Back to the future. Ann Intern Med 1997; 126:983-985.
58. + count of 500 cell/μl. Drugs 1996; 49:4-8.
59. Fessel WJ. Human immunodeficiency virus (HIV) RNA in plasma as the preferred target for therapy in patients with HIV infection: a critique. Clin Infect Dis 1997; 24:116-122.
60. + count using IgA and clinical signs in HIV-seropositive i.v. drug users. Infection 1997; 25:117-120.
61. Darbyshire J. Perspectives in drug therapy of HIV infection. Drugs 1995; 49:1-3.
62. Lange JMA. Changing therapy in HIV. AIDS 1996; 10:S27-S30.
63. Lange JMA. Current problems and the future of antiretroviral drug trials. Science 1997; 276:548-550.
64. Schnittman SM and Fox L. Preliminary evidence for partial restoration of immune function in HIV-type 1 infection with potent antiretroviral therapies: Clues from the 4th Conference on Retroviruses and Opportunistic Diseases. AIDS Res Hum Retroviruses 1997; 13:815-818.
65. Sandstrom E and Oberg B. Antiviral therapy in human immunodeficiency virus infections. Current status (part I). Drugs 1993; 45:488-508.
66. Richman DD, Kornbluth RS and Carson DA. Failure of dideoxynucleotides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 1987; 166:1144-1149.
67. Stagg MP, Cretton EM, Kidd L, Diasio RB and Sommadossi JP. Clinical pharmacokineticx of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of cytotoxic catabolites, 3′ amino-3′-deoxythymidine. Clin Pharmacol Ther 1992; 51:668-676.
68. Hollweg M, Riedel RR, Goebel FD, Schick U and Naber D. Remarkable improvements of neuropsychatric symptoms in HIV-infected patients after AZT-therapy. Klinische Wochenschnift 1991; 69:409-412.
69. Day JJ, Grant I, Atkinson JH, Brysk LT and McCuthan JA. Incidence of AIDS dementia in a two-year follow-up of AIDS and ARC patients on initial phase II zidovudine placebo controlled study. J Neuropsych Clin Neurosc 1997; 4:15-20.
70. Maggiolo F, Taras A, Pravettoni G, Leone M, Ingrosso A and Suter F. Zidovudine and thymus humoral factor gamma-2 in the treatment of HIV infection: Preliminary clinical experience. Infection 1997; 25:35-40.
71. Centers for Disease Control and Prevention. Update. Provisional recommendations for chemoprophylaxis after occupational exposure to human immunodeficiency virus. MMWR 1996; 45:468-472.
72. Easter PG. Prophylaxis after occupational exposure to HIV. BMJ 1997; 315:557-558.
73. th Conference on retrovirus and opportunistic Infection 1997.
74. Conner EM, Sperling RS and Gelber R. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment N Engl J Med 1994, 331:1173-1180.
75. Sperling SR, Shapiro DE and Coombs RW. maternal viral load, zidovudine treatment and the risk of transmission of HIV-1 from mother to infant. N Engl J Med 1996; 335:1621-1629.
76. Melvin AJ and Frentel LM. Prevention of mother-to-infant transmission of HIV-1. Mol Med Today 1997; 3:842-845.
77. Balsley J. Efficacy of zidovudine in preventing HIV transmission from mother to infant. Am J Med 1997; 102:45-46.
78. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL and Diamond GR. A controlled trial of early versus late treatment with zidovudine in symptomatic HIV infection. N Engl J Med 1992; 326:437-443.
79. Struble KA, Pratt RD and Gitterman SR. Toxicity of antiretroviral agents. Am J Med 1997; 102:65-67.
80. Maganani M, Rossi L, fraternale A, Casabianca A , Braudi G, Benatti U and De Flora A. Targeting antiretroviral nucleotide analogues to macrophages. J Leukoc Biol 1997; 62:133-137.
81. Dolin R, Amato DA and Fischl MA. The efficacy of zidovudine compared to didanosine in patients with advanced HIV-1 infection and little or no previous experiences with zidovudine. Arch Intern Med 1995; 155:961-974.
82. Spruance SL, Pavia AT and Deterson D. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double blind clinical trial. Ann Intern Med 1994; 120:360-368.
83. Adkins JC, Peters DH and Faulds D. Zalcitabine: an update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997; 53:1054-1080.
84. Manion DJ and Hirsch MS. Combination chemotherapy for human immunodeficiency virus 1. Am J Med 1997; 102:76-80.
85. DeClercq Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem? Int J Antimicrob Agents 1997; 9:21-36.
86. Perry CM and Faulds D. Lamivudine: A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53:1054-1080.
87. Acosta EP and Fletcher CV. Antiretroviral drug interactions. Int J Antimicrob Agents 1995; 5:73-83.
88. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The Caesar Trial. Lancet 1997; 349:1413-1421.
89. Lacey SF and Larder BA. Novel mutation (V75T) in human immunodeficincy virus type-1 reverse transcriptase confers resistance to 2′3′-dihydro-2′3′-dideoxythymidine in cell culture. Antimicrob Agents Chemoher 1994; 38:1428-1432.
90. Lin PF, Samanta H and Rose RE. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170:1157-1164.
91. Blanshard C. Treatment of HIV-related cytromegalovirus disease of the gastrointestinal tract with foscarnet. J Acq Immun Defic Synd 1992; 5:S25-S28.
92. Bacigalupo A, Tedone E and Vanlint MT. CMV prophylaxis with foscarnet in allogenic bone marrow transport recipients at high risk of developing CMV infections. Bone Marrow Transplant 1993; 13:783-788.
93. Gearhart MO and Sorg TB. Foscarnet-induced hypomagnesemia and other electrolyte disorders. Ann Pharmacol 1993; 27:285-289.
94. Chrisp P and Clissold SP. Foscarnet Drugs 1991; 41:104-129.
95. Noormohamed FH, Youle MS, Higgs CJ, Gazzard BG and Lant AF. Renal excretion and pharmacokinetics of foscarnet in HIV seropositive patients: effect of probenecid pretreatment. Br J Clin Pharmacol 1997;43:112-123.
96. Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N and Dailey PJ. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in Macaques. AIDS Res Hum Retroviruses 1997; 13:707-712.
97. Campiani O, Nacci V, Fiorini I, De Filippis M, Garofalo A, Greco G, Novellino E, Altamura S and Di-Renzo L. Pyrrolobenzothiiazepinone and pyrrolobenzoxazepinones: Novel and specific non-nucleoside HIV-reverse transcriptase inhibitors with antiviral activity. J Med Chem 1996; 39:2672-2680.
98. Kukla MJ, Breslin HJ, Pauwels R, Fedde CL, Miranda M, Scott MK, Sherrill RG, Raeymaekers A, van Gelder J, Andries K, Janssen MAC, DeClercq E and Janssen PAJ. Synthesis and anti-HIV activity of 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk]benzodiazepine-2 (1H) one(TIBO) derivatives. J Med Chem 1991; 34:746-751.
99. Goldman ME, Nunberg JH, O'Brien JA, Quintero JC, Schleif WA, Freund KF, Goul SL, Saari WS, Wai JS, Hoffman JM, Anderson PS, Hupe DJ, Emini EA and Stern AM. Pyridinone derivatives specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antitumor activity. Proc Natl Acad Sci USA 1991; 88:6863-6869.
100. Chimrri A, Grasso S, Monforte AM, Monforte P and Zappala M. Anti-HIV agents: synthesis and in vitro anti-HIV activity of novel 1H, 3H-thiazolo[3,4-(a) benimidazoles. Farmaco 1991; 46:925-933.
101. Domagala JM, Bader JP, Gogliotti RD, Sanchez JP, Stier MA, Song Y, Prasad JV, Tummino PJ, Scholten J, Harvey P, Holler T, Gracheck S, Hupe D, Rice WG and Schultz R. A new class of anti-HIV-1 agents targeted toward the micleocapsid protein NCP7: the 2,2′-dithiobisbenzamides. Biorg Med Chem 1997; 5:569-579.
102. Pauwels R, Audries K, Debyser Z, van Daela P, Schols D, Stoffels P, DeVreese K, Woestenborghs R, Vandamme AM, Janssen CM, Anne J, Cauwenbergh G, Desmyter J, Heykants J, Janssen MAC, DeClercq E and Janssen PAJ. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha anilinophenyl acetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA 1993; 90:1711-1715.
103. Baba M, DeClercq E, Tanaka H, Libasawa H, Takashima H, Shiget S and Walker RT, Miyasaka T. Potent and selective inhibition of human mmunodefiency virus by 5-ethyt-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. 1991; 88:2356-2360.
104. Hara H, Fujihashi T, Sakata T, Kaji A and Kaji H. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. AIDS Res Hum Retroviruses 1997; 13:695-705.
105. Murphy RL and Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996; 5:1183-1199.
106. Arion D, Fletcher R, Borkow G, Camarasa M, Balzarini J, Dmitrienko G and Parniak M. Differences in the inhibition of human immunodeficiency virus type 11 reverse transcriptase DNA polymerase activity by analogues of nevirapine and [2′,5′-bis-O-(ter-butyldimethylsily10-3′-spiro-5″- (4″-amino;-1″2″-Oxathiole-2″,2″dioxide] (TASO). Mol Pharmacol 1996; 50:1057-1064.
107. Havlir D, Cheeseman SH, Mclaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M and Richman DD. High dose nevirapine: safety, pharmacokinetics and antiviral effects in patients with immunodeficiency virus type 1 infection. J Infect Dis 1995; 171:537-545.
108. Sandstorm E and Oberg B. Antiviral therapy in human immunodeficiency virus infections. Current status (part II). Drugs 1993; 45:637-653.
109. D'Aquila R, Hughes M and Liou SH. A comparative study of a combination of ridovudine, didanosine and double-blinded nevirapine versus a combination of zidovudine and didanosine. Proc 2nd International Conference of Human Retroviruses and Related Infections. Wash DC 1995.
110. Thomas M and Brady L. HIV integrase: a target for AIDS therapeutics. Trends Biotechnol 1997; 15:167-172.
111. Tan CK, Civil R, Mian A, So A and Dowrey K. Inhibition of the RNase H activity of HIV reverse transcriptase to azidothymidylate. Biochem 1991; 30:4831-4835.
112. Yu M, Poeschla E and Wong-Staal F. Progress towards gene therapy for HIV infection. Gene Ther 1994; 1:13-26.
113. Corallini A, Altavilla G, Pozzi L, Bignozzi F, Negrini M, Rimessi P, Gualondi F and Barbanti-Brodano G. Systemic expression of HIV-1 Tat gene in transgenic mice induces endothelial proliferation of tumors of different histotypes. Cancer Res 1993; 53:5569-5575.
114. Morgan RA Gene therapy for HIV infection. Clin Exp Immunol 1997; 107:41-44.
115. Nabel G, Fox B, Post L, Thompson C and Wolfendin C. Clinical protocol: a molecular genetic intervention for AIDS. Effects of a transdominant negative form of Rev. Hum Gene Ther 1994; 5:79-92.
116. Walker R, Blaese RM, Carter CS and Chang L.. A study of the safety and survival of the adoptive transfer of genetically marked syngenic lympocytes in HIV-infected identical twins. Hum Gene Ther 1993; 4:659-680.
117. Haynes BF, Putman SB and Weinberg JB. Update on the issues of HIV vaccine development. Ann Med 1996; 28:39-41.
118. Yewdell J and Bennick J. Cell biology of antigen processing and presentation of MHC class I molecule restricted T lymphocyte. Adv Immunol 1992; 52:1-123.
119. Wang B, Ugen D and Srikantan V. Gene inoculation generates immune response against HIV-1. PNAS 1993; 90:4156-514160.
120. Riddell SR, Reusser P and Greenberg PD. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromized patients. Rev Infect Dis 1991; 3:S966-S973.
121. Poesschla EM and Wong-Staal F. Gene therapy and HIV disease In:AIDS Clinical Review 1995/1996 P Wolberding. MA Jacobson (eds) pp 1-28, 1996. Marcel Dekker, Inc. New York, Basel, Hong Kong.
122. Vaishnav YN and Wong-Staal F. The biochemistry of AIDS. Ann Rev Biochem 1991; 60:577-630.
123. Gilboa E and Smith C. Gene therapy for infectious diseases: the AIDS model. Trends Genetics 1994; 10:139-144.
124. Sczakiel G and Pawlita M,. Inhibition of HIV-1 replication in human T cells stably expressing antisense RNA. J Virol 1991; 65:468-472.
125. Rhodes A and James W. Inhibition of heterologous strains of HIV by antisense RNA. AIDS 1991; 5:145-151.
126. Duan L, Zhu M, Ozaki I, Zhang H, Wei DL and Pomerantz RJ. Intracellular inhibition of HIV-1 replication using a dual protein-and RNA-based strategy. Gene Ther 1997; 4:533-543.
127. Mergia A, Blackwell J and Chari S. Inhibition of FIV replication by a ribozyme that targets the Rev response element AIDS Res Hum Retroviruses 1997; 13:1333-1338.
128. Symonds RH. Small catalytic RNAs. Ann Rev Biochem 1992; 61:641-671.
129. Wang S, Dolnick B. Quantitative evaluation of intracellular sense:antisense RNA hybrid duplexes. Nucleic Acids Res 1993; 21:4383-4391.
130. Loeb DD, Hutchison CA, Edgell MH, farmerie WG and Swanstrom R. Mutational analysis of human immuodeficiency virus type 1 protease suggests functional homology with aspartic proteinases. J Virol 1989; 63:111-121.
131. Gottinger HG, Sodroski JG and Haseltine WA. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci 1989; 86:5781-5785.
132. Grinde B and Jonassen TO. The HIV proteinase-a target for antiviral agents. Tidsskr Nor Largeforen 1996; 116:2908-2911.
133. Lewis JS 2nd, Terriff CM, Coulston DR and Garrison MW. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin ther 1997; 12:187-214.
134. Robins T and Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993; 6:162-170.
135. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG and Moss B. An inhibitor of the protease blocks maturation of human and siamin immunodeficiency viruses and spread of infection. Proc Natl Acad Sci USA 1990; 87:7472-7476.
136. Barry M, Gibbons S, Back D and Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32:194-209.
137. Bilello JA, Bilello PA, Prichard M, Robins T and Drusano GL. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J Infect Dis 1995; 171:546-551.
138. Rice WG, Baker DC, Schaeffer CA, Graham L, Bu M, Terpening S, Clanton D, Schultz R, Bader JP, Buckheit RW Jr, Field L, Singh PK and Turpin JA. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserver zinc fingers of retroviral nucleocaspid proteins. Antimicrob Agents Chemother 1997; 41:419-426.
139. Salgo M, Beattie D and Bragman K. Saquinavir vs Hivid vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take retonavir. 11th Conference on AIDS, Vancouver British Columbia 1996, 410.
140. Schapiro JM, Winters MA and Stewart F. The effect of high dose saquinavir on viral load and CD4+ T cell counts in HIV-infected patients. Ann Intern Med 1996; 124:1039-1050.
141. Kitchen VS, Skinner C and Ariyoshi K. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345:952-955.
142. Danner Saa, Carr A and Leonard JM. A short term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 328:1528-1533.
143. Eron JJ. Benoit SL and Jemsek J. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995; 333:1662-1669.
144. Steigbigel RT, Berry P and Mellors J. Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK 639) an escalating dose. Third Conference on Retroviruses and Opportunistic Infections 1996, 146.
145. Shetty BV, Kosa MB and Khalil DA. Preclinical pharmacokinetics and distribution to tissue of AG 1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40:110-114.
146. Gathe J Jr, Bukhardt B, Howley P, Conant M, Peterkin J and Chapman S. A randomized phase II study of viracept, a novel HIV protease inhibitor, used in combination with stavudine (d4T) vs stavudine alone. 4th international Conference on AIDS, British Columbia 1996, 413.
147. Perry CM and Benfield A. Nelfinavir. Drugs 1997; 54:81-87.
148. Nagashima K. Mechanism of neuronal damage in AIDS. Hokkaido Igaku Zasshi 1997; 72:37-41.
149. Federici ME, Kline MW, Lutkiewicz VL, Chruch JA, Harris AT, Evans K, Kaul S, Wheeler S. Smaldone L and Dunkle LM. A phase I/II evaluation of stavudine (d4T) in children with HIV infection. Int Antiv News 1996; 4:109-111.
150. Persdsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet HS, Esptein L, Gelbard H, Flamagon E, Reinhard J, Pimucello SJ and Gendelman HE. HIV-I encephalitis in SCID mice. Am J Pathol 1996; 149:1027-1253.
151. Perno CF, Aquaro S, Rosenwirth B, Balestra E, Peichl P, Billich A, Villani N and Calio R. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukoc Biol 1994; 56:381-386.
152. Perno CF, Beramini A, Pesce CD, Milanese G, Capozzi M, Aquaro S, Thaisrivogs S, Tarpley WO, Zon G, D'Agostini C, Rocchi G, Garaci E and Calio R. Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J Infect Dis 1993; 168:1148-1156.
153. Pedersen C, Sandstorm E, Petersen CS, Norkrons G and Gerstft J. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. N Engl J Med 1990; 168:1111-1125.
154. Hersch E, Brewton G, Abrom D, Bartlett J and Galpin J. Dithiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. J Am Med Assoc 1991; 265:1538-1544.
155. Shen RN, Lu L, Jia XQ, Wong ML and Kaiser HE. Naturin: a potent bio-immunomodifier in experimental studies and clinical trials. In vivo 1996; 20:201-209.
156. BHIV Guidelines Coordinating Committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individual. Lancet 1997; 349:1086-1092.
157. Kaplan JE, Masseur H, Jaffe HW and Holmes KK. Preventing opportunistic infections in persons infected with HIV: 1997 Guidelines JAMA 1997; 278:337-338.
158. Klepser ME and Klepser TB. Drug treatment of HIV-related opportunistic infections. Drugs 1997; 53:40-73.
159. Saag MS. Candidate antiretroviral agents for use in postexposure prophylaxis. Am J Med 1997; 102:25-31.
160. Bolognesi DP. Overview of HIV vaccine development Antibiot Chemother 1996; 48:63-67.
161. Stott EJ, Schild GC. Strategies for AIDS vaccines. J Antimicrob Chemother 1996; 37:185-198.
162. Rowe PM. Getting the vaccine strategy right in HIV-1 disease. Lancet 1997; 349:1454.
163. Koff WC and Schultz AM. Progress and challenges toward an AIDS vaccine: Brother, can you spare a paradigm? J Clin Immunol 1996; 16:127-133.
164. Lawler A and Cohen J. A deadline for an AIDS vaccine. Science 1997; 276:1184-1185.
165. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B and Weiner DB. Development of a multicomponent vaccine for HIV-1. Vaccine 1997; 15:879-883.
166. Wagner L. A vaccine against AIDS. Hope at last. Tenn Nurse 1997; 60:19-21.
167. Ben Yedidia T and Arnon R. Design of peptide and porypeptide vaccines. Curr Opin Biotechnol 1997; 8:442-228.
168. Moore J and Trkola A. HIV type 1 coreceptors, neutralisation serotypes, and vaccine development AIDS Res Hum Retroviruses 1997; 13:733-736.
169. Wong-Staal. Highlights from the University of California San Diego Center for AIDS Research. AIDS Res Hum Retroviruses 1997; 13:733-736.
170. Oxford JS and Jeffs SA. New scientific developments towards an AIDS vaccine: report on a workshop organized by EU program EVA entitled Novel approaches to AIDS vaccine development held at the Institute Pasteur, Paris 1995. Vaccine 1996; 14:1712-1717.
171. Lever AML. HIV genetic variation: Clinical importance. J Infection 1997; 34:195-199.
172. Najera I, Holguin A and Quinones-Mateu ME. pol Gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 69:23-31, 1996.
173. Havlir DV, Eastman S, Gamst A and Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1994; 70:7894-7899.
174. Borman AM, Paulous S and Clavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance in the presence and absence of the drug. J Gen Virol 1996; 77:419-426.
175. Richman DD, Havlir D, Corbeil J. Nevirapine resistance mutations of human immunodeficiency virus type-1 selected drug therapy. J Virol 1994, 68: 1660-1666.
176. Molla A, Korneyeva M and Gao Q. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2:760-766.
177. Coudra JH, Holder DJ and Schleif WA. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996; 70:8270-8276.
178. Mayers DL. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs. Am J Med 1997 102:70-75.
179. Roberts NA. Drug resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 1995; 9:S 27-S 32.
180. Lori F, Malykh AG, Foli A, Maserati R, Antoni A, Minoli L, Padrini D, Antoni A, Barchi E, Jensen H, Wainberg M, Gallo R and Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type-1 resistance. AIDS Res Hum Retroviruses 1997; 13:1403-1406.
181. Johnson VA, Merrill DP and Videler JA. Two-drug combinations of zidovudine, didanosine and recombinant interferon-alpha A inhibited replication of zidovudine-resistant human immunodeficiency virus type-1 synergistically in vitro. J Infect Dis 1991; 164:646-655.
182. Shafer RW, Iversen AK and Winters MA. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type-1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis 1995; 172:70-78.
183. Merrill DP, Moonis M, Chou TC and Hirsch MS. Lamivudine or stavudine in two and three drug combinations against human immunodeficiency virus type-1 replication in vitro. J Infect Dis 1996; 173:335-364.
184. ACTG 290 Protocol Team. A phase II randomized study of the virologic and immunologic effects of d4T versus DDI versus zidovudine plus d4T versus zidovudine plus DDI in HIV infected patients with CD4 cell counts between 300-600 cubic millimeter and greater than 12 weeks zidovudine experience. ACTG 290 Interim Review Results. 1996.
185. Junker U, Baker J, Kalfoglou C, Veres G, Kanesshima H and Bohnlein E. Antiviral potency of drug\gene therapy combinations against HIV type 1. AIDS Res Hum Retroviruses 1997; 13:1395-1399.
186. Hochster H, Dieterich D and Bozzette S. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990; 113:111-117.
187. Grasela TH, Walamonder CA, Beltangady M and Knupp CA. Risk factors for pancreatitis in phase I trials of didanosine. Clin Pharmacol Ther 1992; 53:126.
188. Yarchoan R, Perno CF, Thomas RV, Klecker RW, Allain JP and Wills RJ. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single and alternating with zidovudine (AZT). Lancet 1988; 1:76-81.
189. Yarchoan R, Lietzau JA and Nguyen BY. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169:9-17.
190. Carpenter CCJ, Fischl MA, Hammer SM, Hirch MS, Jacobsen DM and Katzenstein DA. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. JAMA 276:146-154, 1996.
191. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JSG, Richman DD, Saag MS, Schooley RT, Thompson MA, Vellq S, Yeni PO and Volberding PA. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the international AIDS Society-USA Panel. JAMA 1997; 277:1962-1969.
192. Carey PB, Lloyd J and Timmins D. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349:1837.
193. Briant L and Devaux C. Baseline HIV type I load predicts the long-term clinical outcome of infected patients. The 'positive feedback theory'. Immunol Lett 1997; 35:123-125.
194. Gibaldi M. The eleventh international conference on AIDS: cautious celebration in Vancouver. J Clin Pharmacol 1997; 37:20-24.
195. Ernst E. Complementary AIDS therapies: the good, the bad and the ugly. Int J STD AIDS 1997; 8:281-285.
196. DeCock KM. Guidelines for managing HIV infection. BMJ 1997; 315:1-2.
197. Dwyer DE and Kesson AM. Advances in antiviral therapy. Curr Opin Pediatr 1997; 9:24-30.
198. von Overbeck J and Iten A. HIV infection: future perspective for a so-called fatal disease? Schweiz Med Wochenschr 1997; 127:521-527.
199. Whitley RJ. The past as preclude to the future: history, status and future of antiviral drugs. Ann Pharmacother 1996, 30:967-971.
200. Valenti P, Fabbri G, Rampa A, Bisi A and Belluti F. Synthesis of a series of homopterocarpane derivatives with potential antitumor and anti-AIDS activity 1997; 52:13-19.